European Journal of Endocrinology · 2014 · 104 citations · 20 references
MedicineOncologyPharmacologyEndocrine OncologyMetastasisOncology PharmacotherapyThyroid CancerTyrosine Kinase InhibitorsHürthle Cell CarcinomaHürthle Cell LesionsMetastatic Tumors To The ThyroidPoorly Differentiated Thyroid CarcinomaSorafenib TherapyTherapeutic Tyrosine Kinase InhibitorsTumor Response EvaluationTyrosine Kinase Inhibitor Therapy
OBJECTIVE: Tyrosine kinase inhibitors (TKIs) are used to treat patients with advanced thyroid cancers. We retrospectively investigated the efficacy of TKIs administered outside of clinical trials in metastatic sites or locally advanced thyroid cancer patients from five French oncology centers. DESIGN AND METHODS: THERE WERE 62 PATIENTS (37 MEN, MEAN AGE: 61 years) treated with sorafenib (62%), sunitinib (22%), and vandetanib (16%) outside of clinical trials; 22 had papillary, five had follicular, five had Hürthle cell, 13 had poorly differentiated, and 17 had medullary thyroid carcinoma (MTC). Thirty-three, 25, and four patients were treated with one, two, and three lines of TKIs respectively. Primary endpoints were objective tumor response rate and progression-free survival (PFS). Sequential treatments and tumor response according to metastatic sites were secondary endpoints. RESULTS: Among the 39 sorafenib and 12 sunitinib treatments in differentiated thyroid carcinoma (DTC) patients, partial response (PR) rate was 15 and 8% respectively. In the 11 MTC patients treated with vandetanib, 36% had PR. Median PFS was similar in second-line compared with first-line sorafenib or sunitinib therapy (6.7 vs 7.0 months) in DTC patients, but there was no PR with second- and third-line treatments. Bone and pleural lesions were the most refractory sites to treatment. CONCLUSIONS: This is the largest retrospective study evaluating TKI therapies outside of clinical trials. DTC patients treated with second-line therapy had stable disease as best response, but had a similar median PFS compared with the first-line treatment.
20
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Cosimo Durante, Nadia Haddy, E. Baudin et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 1.7K citations
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Vandana G. Abramson, Andrea B. Troxel, Anoma Nellore et al. · Journal of Clinical Oncology · 2008 · 679 citations · Full text
Medicine, Oncology, Pharmacology +6
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
Richard T. Kloos, Matthew D. Ringel, Michael V. Knopp et al. · Journal of Clinical Oncology · 2009 · 543 citations · Full text
Medicine, Oncology, Pharmacotherapy +17